GE HealthCare has revealed plans to launch its macrocyclic, nonionic MRI gadolinium-based contrast agent in "a number of" European countries this year under the name Pixxoscan.
The company said the gadobutrol contrast agent helps with visualizing abnormal structures or lesions as well as differentiating between healthy and pathological tissue. In line with the reference product, Gadovist, Pixxoscan (gadobutrol) is indicated for use in adults, adolescents, and children of all ages for contrast enhancement in cranial and spinal MRI and magnetic resonance angiography. GE added that it is also indicated for whole-body imaging.
GE highlighted gadobutrol's high relaxivity and formulation at twice the concentration of gadolinium ions. It said this reduces injection volume by half compared with other gadolinium-based contrast agents.
Pixxoscan's packaging will also consist of glass vials, ready-assembled plastic prefilled syringes, and larger volume +Pluspak polypropylene bottles.
The company added that the agent will be produced in compliance with current Good Manufacturing Practices (cGMP), with testing being done at its primary and secondary manufacturing sites in Norway. Once approved, it will then be labeled and packed for shipping.
Pixxoscan has been reviewed using a regulatory decentralized procedure with marketing authorization already in place in Austria and pending approval. In France, Pixxoscan will be known as Pixcyclic, according to GE.
![Overview of the study design. (A) The fully automated deep learning framework was developed to estimate body composition (BC) (defined as subcutaneous adipose tissue [SAT] in liters; visceral adipose tissue [VAT] in liters; skeletal muscle [SM] in liters; SM fat fraction [SMFF] as a percentage; and intramuscular adipose tissue [IMAT] in deciliters) from MRI. The fully automated framework comprised one model (model 1) to quantify different BC measures (SAT, VAT, SM, SMFF, and IMAT) as three-dimensional (3D) measures from whole-body MRI scans. The second model (model 2) was trained to identify standardized anatomic landmarks along the craniocaudal body axis (z coordinate field), which allowed for subdividing the whole-body measures into different subregions typically examined on clinical routine MRI scans (chest, abdomen, and pelvis). (B) BC was quantified from whole-body MRI in over 66,000 individuals from two large population-based cohort studies, the UK Biobank (UKB) (36,317 individuals) and the German National Cohort (NAKO) (30,291 individuals). Bar graphs show age distribution by sex and cohort. BMI = body mass index. (C) After the performance assessment of the fully automated framework, the change in BC measures, distributions, and profiles across age decades were investigated. Age-, sex-, and height-adjusted body composition reference curves were calculated and made publicly available in a web-based z-score calculator (https://circ-ml.github.io).](https://img.auntminnieeurope.com/mindful/smg/workspaces/default/uploads/2026/05/body-comp.XgAjTfPj1W.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
